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ABSTRACT 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and is 
considered the predominant cause of dementia worldwide. Pathologically, the 
disease has been attributed to excessive accumulation of amyloid-β peptide and 
hyperphosphorylated tau protein leading to the formation of amyloid plaques and 
tau tangles, respectively. Currently, management of AD is extensively based on 
cholinesterase inhibitors, such as donepezil (DPZ), which provide symptomatic 
improvement. While there is no disease-modifying treatment, our lab has shown 
that tolfenamic acid (TA), a non-steroidal anti-inflammatory drug (NSAID), has 
potential disease-modifying properties independent of its anti-inflammatory effects. 
Thus, here we intended to compare it with DPZ, the most commonly prescribed 
treatment for AD, on behavior and tau pathology biomarker levels using an hTau 
transgenic mouse model and an in vitro model. A prototypical NSAID, ibuprofen 
(IBP), was used to further confirm that TA’s effects are independent of its anti-
inflammatory properties. Our findings show that total tau and its 
hyperphosphorylation levels were reduced in TA and DPZ treated mice, and IBP 
had no such effects on these markers. Treatments that reduced tau levels provided 
consistent improvement of cognitive performance as measured by the Morris 
Water Maze (MWM). Further we demonstrated TA effects on neuroblastoma cell 
line in which both TA and DPZ reduced total tau protein level, but not ibuprofen. 
Keywords: Tolfenamic Acid, Donepezil, Tau Pathology, Cognitive Performance, 
Alzheimer’s Disease, Comparative Study. 
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INTRODUCTION   
Non-steroidal anti-inflammatory drugs (NSAIDs) are known as COX-inhibitors 
and are used to treat a variety of diseases. Due to their anti-inflammatory 
properties, epidemiological studies strongly proposed NSAIDs for the 
management of Alzheimer’s disease (AD); however, their potential benefits were 
not substantiated in clinical trials (reviewed in Imbimbo et al., 2010). 
Cyclooxygenase inhibition is a well characterized anti-inflammatory mechanism by 
which NSAIDs prevent the formation of eicosanoids and ultimately reduce 
formation of prostaglandins (Rao and Knaus 2008), Figure 1. In addition to their 
canonical molecular target, studies have suggested a polyvalent effect for NSAIDs 
in AD underlying pathogenesis. Studies have indicated that NSAIDs lower amyloid 
β42, activate peroxisome proliferator-activated γ, prevent NF-kB translocation and 
affect other molecular targets (Lleo et al., 2007).  
In addition to non-indicative features such as neuroinflammation, AD is 
characterized by presence of extracellular amyloid β plaques and intracellular 
neurofibrillary tangles. These pathologic aggregates are composed mainly of 
amyloid β and hyperphosphorylated tau protein and are considered diagnostic 
biomarkers that distinguish AD from other neurodegenerative diseases (Sperling 
et al., 2014). Further, studies have shown that amyloid pathology is an upstream 
event that occurs years before symptoms become apparent (Bloom 2014). On the 
other hand, tau pathology is a late event and correlates best with cognitive 
impairments (Nelson et al., 2013).  The underlying mechanism of tau toxicity is not 
resolved; however, tau protein is abnormally hyperphosphorylated in AD, the main 
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component of tau tangles (Stoothoff and Johnson 2005). Numerous pathogenic 
sites have been identified in abnormally hyperphosphorylated protein tau  
indicating that phosphorylation of certain sites, such as pSer-262, pSer-356, pSer-
214 and pThr-231, reduces binding affinity of tau to microtubules (Hasegawa et 
al., 1992; Schneider et al., 1999; Cho and Johnson 2003; Hanger et al., 2010).  
Further, different phosphorylation events have been shown to be associated with 
different stages of tau pathology; pThr-153, pThr-231, and pSer-262 epitopes were 
associated with pre-tangle, non-fibrillar tau; while, pSer-404/pSer-396, pSer-
202/pSer-199, and pThr-205 epitopes were associated with filamentous tau 
(Augustinack et al., 2002; Kimura et al., 1996). In addition, some reports indicated 
involvement of Specificity protein 1 (Sp1), a transcription factor, in regulating tau 
gene expression (Heicklen-Klein and Ginzburg 2000; Santpere et al., 2006).  
Cholinergic pathways play an important role in memory and learning 
(Hasselmo 2009). In AD, the source of cortical cholinergic innervation, nucleus 
basalis of Meynert in the basal forebrain, undergoes severe neurodegeneration 
(Mesulam M. 1976; Whitehouse et al., 1918). This discovery and others have 
introduced acetylcholinesterase inhibitors (AChEIs) to be an integral part in the 
management of AD (recently reviewed in Hampel et al., 2018). Thus, currently 
donepezil (DPZ), tacrine, and rivastigmine are approved AChEIs for the 
management of AD (Hansen et al., 2008). DPZ is the most commonly used for 
treatment of AD due to good oral bioavailability and relatively fewer side effects 
compared with other AChEIs (Prickaerts et al., 2017). However, these treatments 
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do not prevent the disease progression and provide only palliative effects (Takeda 
et al., 2006). 
Previously, we have shown that tolfenamic acid (TA), although an NSAID, 
ameliorates AD related biomarkers by mechanisms independent of its anti-
inflammatory properties (Adwan et al., 2011;  Subaiea et al., 2013; Adwan et al., 
2014; Adwan et al., 2015; Subaiea et al., 2015), Figure 2. Thus, in this study we 
intended to compare the effects of TA with donepezil (DPZ) on tau pathology 
biomarkers and memory performance using a hTau transgenic mouse model. 
Ibuprofen (IBP), a prototypical NSAID, was used here to further demonstrate that 
TA works through COX-independent pathways. In addition, we further 
demonstrated effects of aforementioned treatments in a lead-exposed in vitro 
model using SH-SY5Y neuroblastoma cell line.    
MATERIALS AND METHODS  
Animals and treatments:  
Transgenic mice strain of B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J were 
obtained from Jackson lab (Bar Harbor, ME, USA). These mice express 
exclusively human tau isoforms (3R and 4R). The transgene includes: coding 
sequencing, intronic regions, and regulatory elements. These mice develop 
hyperphosphorylated tau and accumulation of tau tangles around three months of 
age. While, cognitive impairment has been characterized in this strain around six 
months of age. These mice carrying the transgene were bred and genotyped at 
the animal facility at the University of Rhode Island. At age of 5-8 months, mice 
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were assigned randomly to four treatment groups with n of 10 in each group as 
follows: (1) carrier control (CC) administered corn oil as a vehicle, (2) carrier 
treated with TA 5 mg/Kg, (3) carrier treated with DPZ of 1mg/Kg, and (4) carrier 
treated with IBP 62.5 mg/Kg. All treatments were purchased form Sigma and 
administered via oral gavage prior and during behavioral testing for 34 days as 
shown in Figure 3. TA dose was chosen based on a previous work; while, IBP and 
DPZ doses were chosen from literature, cited in the discussion section. Animals 
were kept on a cycle of 12:12 light-dark and room temperature was maintained at 
22 ± 2 °C.  Food and water were made available, ad-libitum, and body weight was 
assessed every 3-4 days. Animals were euthanized by exposure to CO2 inhalation 
24 h after the last day of treatment administration. Brain tissues were extracted 
and stored at -80 °C. All procedures and protocols for this study were approved by 
the URI Institutional Animal Care and Use Committee (IACUC). Animals during 
this study were also under continuous supervision by the URI animal facility staff.   
Behavioral studies:  
Morris Water Maze (MWM) was performed following a published method to 
assess spatial learning and memory performance on the 15th day of treatments 
administration (Morris et al., 1982). A plastic tank with 48 inches diameter and 30 
inches height was used. The tank was made opaque with non-toxic paint (Crayola, 
New York City, NY) and filled with water to a depth of 14 inches. Along the tank’s 
wall, visual cues were placed high up on the tank, and the tank was visually divided 
into four quadrants (SW, SE, NW, and NE). An escape platform (10 cm2) was 
submerged 1 cm below the surface of the water in one of the quadrants, known as 
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the platform zone (PFZ), and the position was fixed during all trials. For each trial, 
the mice were placed facing the wall and starting points were randomly assigned. 
Water temperature was maintained at 25+/-2 °C during behavior testing. A 
computerized video-tracking system (ObjectScan, Clever Sys. Inc., Reston, VA) 
was used to analyze the path of each mouse during each trial of the behavior 
testing.  
Acclimation-Day 0, before the beginning of memory training, acclimation was 
performed for one day. In this acclimation trial with no platform placed, each mouse 
was allowed to swim for 60s. Acquisition trials-Day1-Day7, commenced on the 15th 
day of drug administration: During these trials, a platform was placed as described 
above with a fixed position and each mouse received three daily training sessions 
with 20 min inter-trial interval. The starting points were randomly assigned, and 
mice were given 60s period of swimming to find the platform. If they failed to find 
it in the given time, mice were guided towards it, and allowed to sit for 30s; latency 
time was recorded and analyzed. Showing a preference towards the quadrant that 
had the platform, would be an indication that mice had developed a memory of the 
correct quadrant.  
Probe trials-commenced on the 24th and 34th days of drug administration: 
during probe trials, the platform was removed, and mice allowed to swim for 60s. 
Developing a preference to the location of the platform, correct quadrant, would be 
an indication that mice have developed a memory of the correct place. Percentage 
of number of crossing of the correct quadrant was calculated for treatment groups 
and compared with their control counterpart.  
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Protein Extraction and Western Blotting: 
Using radio-immunoprecipitation lysis buffer (RIPA) (Sigma Aldrich, MO) 
supplemented with 0.1% protease inhibitor cocktail and 5µL phosphatase inhibitor, 
cerebral cortices samples were homogenized and incubated on ice for 30 min. 
Then for 5 min, homogenates were sonicated and vortexed. After that, at 10.000 
× g, homogenates were centrifuged for 20 min and supernatant were collected and 
stored at −80 °C. Micro BCA kit (Thermo Scientific, Waltham, MA) was used to 
determine total protein concentration. Twelve per cent SDS-Page gels were 
prepared, and 30 µg total protein is loaded followed by transferring to 
Polyvinylidene Fluoride (PVDF) membranes (GE, Piscataway, NJ). Following 
transferring, membranes were blocked for 1 h at room temperature with either 5% 
bovine serum albumin (BSA) or 5% non-dry milk in Tris buffered saline + 0.1% 
Tween 20 (TBST). Then at dilution of 1:1000, membranes were incubated 
overnight with primary antibodies of interest: Rabbit Anti-CDK5, Rabbit Anti-
GAPDH, Mouse Anti-Tau-46, Rabbit Anti-Ser404, and Mouse Anti-Sp1 (Cell 
Signaling Technology, Danvers, MA). On the following day, membranes were 
washed and exposed to either IRDye® 680LT infrared dye or IRDye®800LT 
Infrared Dye (LI-COR Biotechnology, NE), goat anti-mouse/goat anti-rabbit diluted 
at 1:10000 for 1 h. Finally, Odyssey® Infrared Imaging System (Li-Cor, NE) was 
used to detect and quantify infrared signal of Western Blot bands.  
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RNA synthesis, cDNA, and Real Time PCR:  
TRIzol® Reagent method was used (Invitrogen, Carlsbad, CA) for RNA 
isolation from cerebral cortex tissues followed by Nanodrop (Thermo Scientific, 
Wilmington, DE) to check integrity. Following manufacturer’s instructions (Bio-Rad, 
Hercules, CA), cDNA was synthesized using iScriptTM Select cDNA synthesis kit 
in which samples were incubated for 90 min at 42 oC; and then to terminate the 
reaction, samples were further incubated for 5 min at 85 oC using MJ Research 
MiniCycleTM (Bio-Rad, Hercules, CA). Primers for Tau and GAPDH were obtained 
from Invitrogen (Carlsbad, CA) as follows: Tau sense: 5¢-AGTAAAGGGC 
AGCGGACCAGCGGCG-3¢ and antisense: 5¢-GGCGCGCGCGGCGAGA GGGC 
GCGTT-3¢; GAPDH sense:5¢-TGGTGAAGCAGGCATCTGAG-3¢and anti-sense: 
5¢-TGCTGTTGAAGTCGCAGGAG-3¢. Real time PCR reaction mix was prepared 
using 1.5 µM of cDNA, 1 µL of each primer, 9 µL of nuclease free water, and 12.5 
µL of SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA). 7500 
Real Time PCR System (Applied Biosystems, Foster City, CA) was used for RT-
PCR experiments following the standard protocols:  samples were incubated at 5 
oC for 2 min, followed by 95 C for 10 min and 40 cycles of 95 oC for 15 sec; then 
60 oC for 1 min. GAPDH was used as endogenous control with data was analyzed 
with relative quantifications.   
Cell Culture and Western blotting:  
To further investigate TA and DPZ effects on a lead (Pb)-exposed model from 
our laboratory to induce certain markers such as Specificity protein 1 (Sp1), human 
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neuroblastoma cells (SH-SY5Y) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). DMEM/F12 medium (Sigma-Aldrich, MO) 
supplemented with 10% fetal bovine serum (FBS), penicillin (10 IU/mL), 
streptomycin (10 mg/mL), and glutamine 2 mmol/L were used for culturing and 
maintaining the cells. Following published methods (Adwan, et al., 2014), cells 
were sub-cultured at 105 cells/mL in six well plate and upon 80% confluency cells 
were differentiated for one week using 10mM all-trans retinoic acid (Sigma Aldrich, 
St. Louis, MO) in DMEM/F12 medium supplemented with 1% FBS, penicillin (10 
IU/mL), streptomycin (10 mg/mL), and glutamine 2 mmol/L. Medium was changed 
every 48 h and neurite outgrowth was examined every two days, as described 
before (Adwan et al., 2014; Jamsa et al., 2004).  After differentiation, cells 
sequentially were exposed to lead (Pb) acetate 10 mM for two days to induce 
certain markers, cells were then exposed to TA, DPZ, and IBP diluted in DMSO 
for 72 h with the following concentrations: 5 µM, and 25 µM. DMSO of 0.05% is 
used and maintained for controls and treatments. Cells then harvested and protein 
extraction performed according to manufacturer’s protocol (Bio-Rad, Hercules, 
CA). Western blot experiments were performed as stated previously.   
Statistical analysis: 
Proper statistical tests were used including Student’s t-test, or ANOVA 
analysis of variance as indicated. Dunnett's test for multiple comparisons was 
further used if necessary. Graph pad prism 7.0 computer software (La Jolla, CA, 
USA) was used and p<0.05 were considered to be statistically significant. Data 
were represented as mean ± SEM. 
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RESULTS 
TA and DPZ treated mice showed consistent improvement in cognitive 
performance 
Spatial learning and memory performance were assessed using MWM, in 
which mice have to navigate through and use visual cues to locate a hidden escape 
platform. Reference memory is measured by preference developed to the escape 
platform position. Behavioral assessment commenced for acquisition trials on the 
15th day of treatments administration for 8 days shows that TA-treated mice 
showed a sustained and consistent improvement in cognitive performance as well 
as DPZ-treated mice to lesser degree during the acquisition trials, Figure 4 (a-c); 
while, IBP treated mice showed fluctuated performance compared with the CC 
group. However, all treatment groups showed a non-significant trend of improved 
memory performance on probe trials on the 24th and 34th days of treatments 
administration, Figure 4 (d, and e).  
TA reduces total tau and p-tau protein levels, but not cyclin-dependent kinase 5 
(CDK5) protein levels  
Following administration of TA for 34 days, total tau and p-tau (Ser404) 
expression levels were reduced in cerebral cortex compared with the CC group 
determined by western blot analysis as shown in Figure 5, p= 0.0011 and p= 
0.0017 respectively determined by two-tailed unpaired t-test. Western blot analysis 
indicates that TA had no effect on CDK5 expression levels, Figure 6.  
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DPZ reduces total tau and p-tau protein levels, but not CDK5                  
Next, we investigated whether DPZ had an impact on tau related biomarkers. 
Western blot analysis shows reduced total tau and p-tau (Ser404) protein levels in 
cerebral cortices of DPZ-treated mice compared with the CC group, p= 0.0020 and 
p=0.0021, respectively determined by two-tailed unpaired t-test, Figure 7. We did 
not observe effects on CDK5 expression levels in DPZ-treated mice compared with 
the CC group, Figure 8.    
IBP doesn’t lower total tau, p-tau, or CDK5 protein levels 
Further, we used IBP here as a negative control, prototypical NSAID, to 
demonstrate whether effects of TA on tau pathology are related to its anti-
inflammatory properties. IBP had no effect on total tau and p-tau (Ser404) after 34 
days of drug administration in this model analyzed using two-tailed unpaired t-test, 
Figure 9. In addition, we did not observe changes in CDK5 protein levels, Figure 
10.    
Tau mRNA levels in cerebral cortices of mice treated with TA, DPZ, and IBP 
Following exposure for 34 days, we observed a non-significant trend of 
lowering effects on tau mRNA in cerebral cortices of mice treated with 
aforementioned treatments, Figure 11. Data were analyzed using two-tailed 
unpaired t-test.  
TA and DPZ lower Sp1and Total tau protein levels in vitro, but not IBP 
After exposing SH-SY5Y cells to Pb for 48 h as described in the method 
section, treating cells with TA and DPZ of a 5 µM and 25 µM for 72 h resulted in a 
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significant reduction of Sp1 protein level. In addition, DPZ reduced total tau level 
significantly; and to some extent TA. However, we didn’t observe such effects with 
IBP, Figure 12. Data were analyzed using one-way ANOVA.  
DISCUSSION 
Tau pathology is a key contributor to many neurodegenerative diseases 
including AD and given the heterogenicity of AD, targeting multiple points of the 
pathogenesis might be more efficacious than a single node (Iqbal et al., 2005). 
Previously in wild type mice, we have shown the ability of TA to lower AD related 
Aβ pathology via a transcriptional pathway (Adwan et al., 2011). These findings 
were further confirmed in APP transgenic mice in which we reported a reduction in 
amyloid-related pathology biomarkers with improved cognitive functions (Subaiea 
et al., 2013; Adwan et al., 2014; Adwan et al., 2015; Subaiea et al., 2015). In 
addition, we showed the ability of TA to reduce beta site APP cleaving enzyme 1 
(BACE1) enzyme activity and gene expression as well as Sp1 expressions in APP 
mice (Adwan et al., 2014). Furthermore, we demonstrated recently the efficacy of 
TA in improving cognitive function in hTau transgenic mice accompanied with 
reduced total tau and p-tau levels, pThr181 and pThr-231, in the frontal cortex and 
cerebellum demonstrated by Western blot and immunohistochemistry analysis 
(Chang et al., 2018).  
In this study we compared the behavioral performance of TA and DPZ treated 
groups. The MWM analysis showed that TA provided sustained and consistent 
improvement in memory performance as well as DPZ to a lesser degree during the 
acquisition and probe trials; while, IBP-treated mice showed fluctuation in their 
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daily performance, Figure 4. Previously, we showed that TA doesn’t affect swim 
speed or velocity ruling out the possibility that such improvements might be due to 
improved overall well-being (Change et al., 2018; Leso et al., 2019). Further, a 
previous report on DPZ also showed that DPZ had no effect on swim speed 
compared with their untreated counterparts in APP transgenic model (Easton et 
al., 2013).  
Western blot analysis showed a reduction in total tau and p-tau (Ser404) in 
cerebral cortices of mice treated with TA, Figure 5. These results further 
demonstrate the ability of TA to ameliorate tau pathology biomarkers and confirm 
previous work by our lab, cited above, and that it is comparable for DPZ effects, 
Figure 7. It’s well-known that DPZ enhances cognitive function and has been used 
for a long time in AD patients (Rogers et al., 2000). Furthermore, Other studies 
also indicated that DPZ does not solely work at the Ach level, but in fact might 
have disease modifying effects through affecting the amyloid pathology (reviewed 
in Sabbagh et al., 2006). In addition, it has been reported that DPZ affects 
neuroinflammation, tau pathology and neurodegeneration in FTD-17 mouse 
model, line PS19 (Yoshiyama et al., 2010).  
However, Western blot analysis of mice brains treated with IBP didn’t show 
reduction in either total tau or its phosphorylation state, Figure 9. In addition, a 
previous report on IBP showed that IBP didn’t provide significant improvement in 
memory performance tasks using APP23 transgenic mice (Dam et al., 2010). By 
contrast, McKee et al reported different findings that chronic administration of IBP 
for six months ameliorates amyloid and tau pathology in triple transgenic AD mice 
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and improves learning and memory performance (McKee et al., 2008). However, 
these effects on tau pathology might be secondary to the reduction of amyloid β 
accumulation as shown previously (Oddo et al., 2006). In addition, to mention here 
the difference in the duration of treatments and the model we used here as that 
might explain such differences in findings. It’s also worth noting here also  previous 
animal studies showed inconsistent results of IBP’s effects on amyloid pathology 
related biomarkers (reviewed in Gasparini et al., 2004).  
While we observed a significant reduction in the tau protein levels with TA and 
DPZ, mRNA finding suggests these treatments did not affect significantly tau gene 
expression, Figure 11. It has been shown that NSAIDs including TA are treatments 
that have polyvalent effects, of which activating proteasomal-dependent 
degradation pathways inducing degradation of certain targets (Maen and Safe 
2005; Maen et al., 2006). Thus, it is plausible that both TA and DPZ induced tau 
protein degradation through activating cellular degradation pathways without 
affecting its gene expression and that warrants further investigation.  
Although this mouse model exhibits tau pathology related biomarkers with 
manifested cognitive impairment, to our knowledge the inflammatory response has 
not been characterized in this model. We couldn’t detect brain COX2, a typical 
target of NSAIDs, using Western blot analysis. It is possible that COX2 expression 
as an inflammatory mediator is not induced at this age. However, we have 
previously shown in the same model at 18 months old that TA reduces COX2 
expression in presence and absence of tau mouse model (Leso et al., 2019). In 
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addition, using IBP as a control might further support the hypothesis that TA 
ameliorates AD related biomarkers independent of its anti-inflammatory properties.  
Previous work has shown the involvement of Sp1 in the underlying AD 
pathogenesis including regulation of APP and BACE1 gene expression (Brock et 
al., 2008; Christensen et al., 2004; Citron et al., 2008). The in vitro work here shows 
that treating SH-SY5Y cells with TA and DPZ reduced the SP1 protein level; total 
tau level was also reduced significantly with DPZ, and to some degree with TA. 
However, with IBP-treated cells, we didn’t observe any such effects on these 
markers which might further confirms the IBP in vivo findings as shown in Figure 
12. However, including more dose concentrations for TA and IBP might be 
warranted to observe such potential reducing effects on tau expressions.  
It’s worth noting here that this study has several limitations. It’s also possible 
that increasing the treatment doses are needed for the cell culture work to further 
recapitulate concentration-effects for the aforementioned treatments particularly 
for IBP, if any, on examined markers. In addition, adding more NSAIDs with similar 
structure, such as Mefenamic acid, as positive controls will further strengthen our 
hypothesis as that these compounds might show similar effects as TA on the AD 
markers. It’s also possible that the reduction effects observed on tau 
phosphorylation might be related to reduced total tau protein levels rather than 
affecting related potential kinases expression levels/ or activity. Thus, having 
kinase enzyme activity assays and wild type controls will further allow us to 
examine and compare related potential kinase activity/expression and that 
requires further investigation.  
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CONCLUSION 
In summary, this work suggests that TA works through a COX-independent 
pathway ameliorating AD-related biomarkers and that it is comparable with DPZ. 
In addition, treatments that reduced tau pathology biomarkers, namely TA and 
DPZ, provided consistent improvement in the behavioral assessment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16 
 
Figure 1. Representative of biosynthesis of prostanoids and main 
mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). A 
well characterized mechanism of action for NSAIDs is through the inhabitation of 
cyclooxygenase enzymes (COX 1 & 2), interfering with the formation of 
inflammatory mediators (prostaglandins and thromboxanes).    
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Figure 2. Proposed mechanism of action for TA independent of COX-
pathways. TA reduces Sp1 protein level (Maen et al., 2006; Adwan et al., 2011; 
Subaiea et al., 2013) down-regulating tau gene expression. It’s also possible that 
TA interferes with the binding of Sp1 to its target genes including tau, reducing 
their gene expressions and that warrants further investigation.  
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Figure 3. Timeline of treatment administration and behavioral assessment. 
Mice were administered TA, DPZ, IBP, or corn oil for 34 days. Behavioral 
assessment commenced on day 15 beginning with habituation and acquisition 
trials for 8 days. Then, two probe trials were conducted on day 24 and day 34 and 
mice were euthanized on the day 35 and brain tissues were dissected.   
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Figure 4. Spatial learning of hTau carrier mice treated with TA, DPZ, and IBP 
compared to Carrier Controls in the MWM. The escape latency in seconds and 
percentage of number of crossing of the correct quadrant were assessed during 
acquisition trials and probe trials, commenced on the 15th-23rd, 24th, and 34th of 
treatments administration respectively (a-e). Each group contained 8-10 mice and 
each mouse received 3 trial/day during the acquisition trial and MWM experiments 
were conducted as mentioned in section 2.2. Asterisks indicate significant 
difference (two-tailed unpaired t-test and one-way ANOVA tests were used-
*p<0.05, **p<0.0; results were represented as mean ± SEM). 
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Figure 5. Total tau and p-tau (Ser404) protein levels in cerebral cortices of 
mice treated with TA. hTau carrier mice (5-8 months) treated with TA 5 mg/Kg 
for 34 days were compared with the CC group with n of 5 in each group. (a) Total 
Tau (b) Ser404. Asterisks indicate significant difference (two-tailed unpaired t-test-
*p<0.05, **p<0.01; results were represented as mean ± SEM). 
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Figure 6. CDK5 protein levels in cerebral cortices of mice treated with TA. 
hTau carrier mice (5-8 months) treated with TA 5 mg/Kg for 34 days were 
compared with the CC group with n of 5 in each group. Western blot analysis 
doesn’t indicate significant difference between the two groups (two-tailed unpaired 
t-test; results were represented as mean ± SEM). 
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Figure 7. Total tau and p-tau (Ser404) protein levels in cerebral cortices from 
mice treated with DPZ. hTau carrier mice (5-8 months) treated with DPZ 1 mg/Kg 
for 34 days were compared with the CC group with n of 5 in each group. (a) Total 
Tau (b) Ser404. Asterisks indicate significant difference (two-tailed unpaired t-test-
*p<0.05, **p<0.01; results were represented as mean ± SEM). 
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Figure 8. CDK5 protein levels in cerebral cortices of mice treated with DPZ. 
hTau carrier mice (5-8 months) treated with DPZ 1 mg/Kg for 34 days were 
compared with the CC group with n of 5 in each group. Western blot analysis 
doesn’t indicate significant difference between the two groups (two-tailed unpaired 
t-test; results were represented as mean ± SEM). 
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Figure 9. Total tau and p-tau (Ser404) protein levels in cerebral cortices of 
mice treated with IBP. hTau carrier mice (5-8 months) treated with IBP 62.5 
mg/Kg for 34 days were compared with the CC group with n of 5 in each group. (a) 
Total Tau (b) Ser404. Western blot analysis doesn’t indicate significant difference 
between the two groups (two-tailed unpaired t-test; results were represented as 
mean ± SEM). 
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Figure 10. CDK5 protein levels in cerebral cortices of mice treated with IBP. 
hTau carrier mice (5-8 months) treated with IBP 65.2 mg/Kg for 34 days were 
compared with the CC group with n of 5 in each group. Western blot analysis 
doesn’t indicate significant difference between the two groups (two-tailed unpaired 
t-test; results were represented as mean ± SEM). 
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Figure 11. Tau mRNA levels in cerebral cortices of mice treated with TA, DPZ, 
and IBP. Real time-PCR results of tau mRNA levels in cerebral cortices of mice 
(5-8 months) treated with aforementioned treatments for 34 days (a-c), 
respectively. GAPDH was used an endogenous control and data were analyzed 
using two tailed unpaired t-test. Results were represented as mean ± SEM. 
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Figure 12. Sp1 and total tau proteins levels in differentiated SH-SY5Y cells. 
SH-SY5Y cells differentiated and treated with Pb for 48 h followed by 72 h of media 
containing TA, DPZ, or IBP as stated in the method section. Sp1 and tau protein 
levels were normalized to endogenous GAPDH level. Data were analyzed using 
one-way ANOVA with Dunnett's test for multiple comparisons. Results were 
represented as mean ± SEM.  
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